IA与AA治疗急性髓系白血病疗效对比分析

Effects of IA and AA on acute myeloid leukemia

目的 探讨去甲氧柔红霉素＋阿糖胞苷（IA）与阿柔比星＋阿糖胞苷（AA）化疗方案治疗急性髓系白血病的疗效及不良反应.方法 选取急性髓系白血病（AML）患者50例,其中20例采用IA方案治疗,30例采用AA方案治疗.比较两组患者的治疗效果及其不良反应.结果 两组患者的完全缓解率分别为75.0%、73.3%,差异未见统计学意义（P＞0.05）.两组心脏损伤情况比较差异有统计学意义（P＜0.05）,而在骨髓抑制、恶心呕吐及感染等方面的不良反应比较差异未见统计学意义（P＞0.05）.结论 IA与AA在治疗急性髓系白血病临床疗效方面相似,在不良反应中IA化疗方案的心脏毒性作用弱于AA方案,其他不良反应相似.

Objective To investigate the effects and adverse reactions of darubicin plus cytarabine（IA） and aclarubicin plus cytarabine（AA） chemotherapy regimens in the treatment of acute myeloid leukemia. Methods Fifty cases of acute myeloid leukemia （AML） were selected, 20 patients with IA solution treatment, 30 patients with AA solution treatment, the curative effects and adverse reactions of the two groups were compared.Results The complete remission rate was 75.0% and 73.3% in the two groups, the difference was not significant （P〉0.05）. There was significant difference in the heart damage between the two groups （P〈0.05）, and the adverse reaction in bone marrow suppression, nausea and vomiting and infection and other aspects between the two groups had no significant difference （P〉0.05）.Conclusions IA and AA are similar in the treatment of acute myeloid leukemia, and the adverse effects of IA chemotherapy regimen are less toxic than the AA regimen, and other adverse reactions are similar.